Zobrazeno 1 - 10 of 124 pro vyhledávání: '"Dokter WHA"'
2
Akademický článek
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
Autor: van Helden MJ; Byondis BV, Nijmegen, Gelderland, The Netherlands., Zwarthoff SA; Byondis BV, Nijmegen, Gelderland, The Netherlands., Arends RJ; Byondis BV, Nijmegen, Gelderland, The Netherlands., Reinieren-Beeren IMJ; Byondis BV, Nijmegen, Gelderland, The Netherlands., Paradé MCBC; Byondis BV, Nijmegen, Gelderland, The Netherlands., Driessen-Engels L; Byondis BV, Nijmegen, Gelderland, The Netherlands., de Laat-Arts K; Byondis BV, Nijmegen, Gelderland, The Netherlands., Damming D; Byondis BV, Nijmegen, Gelderland, The Netherlands., Santegoeds-Lenssen EWH; Byondis BV, Nijmegen, Gelderland, The Netherlands., van Kuppeveld DWJ; Byondis BV, Nijmegen, Gelderland, The Netherlands., Lodewijks I; Byondis BV, Nijmegen, Gelderland, The Netherlands., Olsman H; Sanquin Research, Amsterdam, The Netherlands., Matlung HL; Sanquin Research, Amsterdam, The Netherlands., Franke K; Sanquin Research, Amsterdam, The Netherlands., Mattaar-Hepp E; Byondis BV, Nijmegen, Gelderland, The Netherlands., Stokman MEM; Byondis BV, Nijmegen, Gelderland, The Netherlands., de Wit B; Byondis BV, Nijmegen, Gelderland, The Netherlands., Glaudemans DHRF; Byondis BV, Nijmegen, Gelderland, The Netherlands., van Wijk DEJW; Byondis BV, Nijmegen, Gelderland, The Netherlands., Joosten-Stoffels L; Byondis BV, Nijmegen, Gelderland, The Netherlands., Schouten J; Byondis BV, Nijmegen, Gelderland, The Netherlands., Boersema PJ; Byondis BV, Nijmegen, Gelderland, The Netherlands., van der Vleuten M; Byondis BV, Nijmegen, Gelderland, The Netherlands., Sanderink JWH; Byondis BV, Nijmegen, Gelderland, The Netherlands., Kappers WA; Byondis BV, Nijmegen, Gelderland, The Netherlands., van den Dobbelsteen D; Byondis BV, Nijmegen, Gelderland, The Netherlands., Timmers M; Byondis BV, Nijmegen, Gelderland, The Netherlands., Ubink R; Byondis BV, Nijmegen, Gelderland, The Netherlands., Rouwendal GJA; Byondis BV, Nijmegen, Gelderland, The Netherlands., Verheijden G; Byondis BV, Nijmegen, Gelderland, The Netherlands., van der Lee MMC; Byondis BV, Nijmegen, Gelderland, The Netherlands., Dokter WHA; Byondis BV, Nijmegen, Gelderland, The Netherlands., van den Berg TK; Byondis BV, Nijmegen, Gelderland, The Netherlands Timo.vandenBerg@byondis.com.; Sanquin Research, Amsterdam, The Netherlands.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Apr; Vol. 11 (4).
Zobrazit plný text záznamu
3
Akademický článek
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Autor: Duro-Sánchez S; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Bellaterra, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Nadal-Serrano M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Lalinde-Gutiérrez M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Bellaterra, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Arenas EJ; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Bernadó Morales C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Morancho B; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain., Escorihuela M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pérez-Ramos S; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Escrivá-de-Romaní S; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Gandullo-Sánchez L; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Pandiella A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Instituto de Biología Molecular y Celular del Cáncer, CSIC, Salamanca, Spain., Esteve-Codina A; NAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain., Rodilla V; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Dijcks FA; Byondis B.V., Nijmegen, the Netherlands., Dokter WHA; Byondis B.V., Nijmegen, the Netherlands., Cortés J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Saura C; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain., Arribas J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Publikováno v: Cancer research [Cancer Res] 2022 Dec 16; Vol. 82 (24), pp. 4670-4679.
Zobrazit plný text záznamu
4
Akademický článek
A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines.
Autor: Coumans RGE; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Ariaans GJA; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Spijker HJ; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Renart Verkerk P; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Beusker PH; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Kokke BPA; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Schouten J; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Blomenröhr M; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., van der Lee MMC; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Groothuis PG; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Ubink R; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Dokter WHA; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands., Timmers CM; Byondis B.V., Microweg 22, 6545 CM Nijmegen, The Netherlands.
Publikováno v: Bioconjugate chemistry [Bioconjug Chem] 2020 Sep 16; Vol. 31 (9), pp. 2136-2146. Date of Electronic Publication: 2020 Aug 25.
Zobrazit plný text záznamu
5
Akademický článek
The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1.
Autor: Nadal-Serrano M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Morancho B; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Escrivá-de-Romaní S; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Medical Oncology Department, Vall d´Hebron University Hospital (HUVH), 08035 Barcelona, Spain., Morales CB; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Luque A; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Escorihuela M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Espinosa Bravo M; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Medical Oncology Department, Vall d´Hebron University Hospital (HUVH), 08035 Barcelona, Spain., Peg V; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Medical Oncology Department, Vall d´Hebron University Hospital (HUVH), 08035 Barcelona, Spain., Dijcks FA; Preclinical R&D, Synthon Biopharmaceuticals BV, 6545 CM Nijmegen, The Netherlands., Dokter WHA; Preclinical R&D, Synthon Biopharmaceuticals BV, 6545 CM Nijmegen, The Netherlands., Cortés J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Saura C; Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Medical Oncology Department, Vall d´Hebron University Hospital (HUVH), 08035 Barcelona, Spain., Arribas J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autónoma de Barcelona, Campus de la UAB, 08193 Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats, 08010 Barcelona, Spain.
Publikováno v: Cancers [Cancers (Basel)] 2020 Mar 13; Vol. 12 (3). Date of Electronic Publication: 2020 Mar 13.
Zobrazit plný text záznamu
6
The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: A new model to study carcinoma-directed immunotherapy
Autor: McLaughlin, PMJ, Harmsen, MC, Dokter, WHA, Kroesen, BJ, van der Molen, H, Brinker, MGL, Hollema, H, Ruiters, MHJ, Buys, CHCM, de Leij, LFMH
Publikováno v: Cancer Research, 61(10), 4105-4111. AMER ASSOC CANCER RESEARCH
The human pancarcinoma-associated epithelial glycoprotein-2 (EGP-2), a M, 38,000 transmembrane antigen also known as 17-1A or Ep-CAM, is commonly used for targeted immunotherapy of carcinomas because it is strongly expressed by most carcinomas. EGP-2
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::cf9b9ac1ec88bfd3683463a2a3bf93ba
https://research.rug.nl/en/publications/f069caf4-9de9-4264-bcfe-1ed610ceb75d
Zobrazit plný text záznamu
7
Interleukin-6-induced STAT3 transactivation and Ser(727) phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components
Autor: Schuringa, JJ, Jonk, LJC, Dokter, WHA, Vellenga, E, Kruijer, W
Publikováno v: Biochemical Journal, 347, 89-96. PORTLAND PRESS LTD
In the present study, signal transducer and activator of transcription 3 (STAT3) Ser(727) phosphorylation and transactivation was investigated in relation to activation of mitogen-activated protein (MAP) kinase family members including extracellular-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::2dbf8cd8c5ee8af1839cbe4aa640672b
https://research.rug.nl/en/publications/162e44f9-8353-4ac0-9585-7aaa42130498
Zobrazit plný text záznamu
8
Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes
Autor: Tuyt, LML, Dokter, WHA, Birbenkamp, K, Koopmans, S.B., Lummen, C, Kruijer, W, Vellenga, E
Publikováno v: Journal of Immunology, 162(8), 4893-4902. AMER ASSOC IMMUNOLOGISTS
In the present study we investigated the possible involvement of the mitogen-activated protein kinase family members extracellular-regulated kinase 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) in mediating IL-6 gene expression in human monocytes, i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::78e70f1a423fe6b3d8faeeb187fc4dde
https://research.rug.nl/en/publications/0526e7d5-08ef-40f6-9713-7df29ce76dd2
Zobrazit plný text záznamu
9
Akademický článek
Unraveling the Interaction between Carboxylesterase 1c and the Antibody-Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice.
Autor: Ubink R; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands. ruud.ubink@synthon.com., Dirksen EHC; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Rouwette M; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Bos ES; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Janssen I; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Egging DF; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Loosveld EM; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., van Achterberg TA; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Berentsen K; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., van der Lee MMC; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Bichat F; Oncodesign, Dijon, France., Raguin O; Oncodesign, Dijon, France., van der Vleuten MAJ; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Groothuis PG; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands., Dokter WHA; Department of Preclinical, Synthon Biopharmaceuticals BV, Nijmegen, the Netherlands.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Nov; Vol. 17 (11), pp. 2389-2398. Date of Electronic Publication: 2018 Aug 09.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje